<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894149</url>
  </required_header>
  <id_info>
    <org_study_id>21/001</org_study_id>
    <nct_id>NCT04894149</nct_id>
  </id_info>
  <brief_title>Prehabilitation and Rehabilitation for Patients With Oesophageal Cancer</brief_title>
  <acronym>PRESO</acronym>
  <official_title>Prehabilitation and Rehabilitation for Patients With Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gabriella Alexandersson von Döbeln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with oesophageal cancer selected for oncological and surgical treatment with&#xD;
      curative intent are offered supervised physiotherapy and home-based training before and after&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with loco-regional oesophageal cancer who will receive neoadjuvant chemotherapy or&#xD;
      chemoradiotherapy followed by surgery and sometimes adjuvant chemotherapy are eligible to be&#xD;
      enrolled in the trial. Study treatment is supervised group training twice weekly and&#xD;
      home-based training three times weekly during neoadjuvant treatment and after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to exercise sessions.</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Percentage of sessions completed out of number of sessions planned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Un-planned interruptions in the prehabilitation/rehabilitation programme</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Percentage of patients having an unplanned interruption of ten days or more of the supervised prehabilitation/rehabilitation programme</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiotherapy</intervention_name>
    <description>Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)</description>
    <arm_group_label>Physiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous&#xD;
             carcinoma in the oesophagus or cardia (Siewert I or II), cT1 N+ or cT2-4a any N, M0,&#xD;
             according to the 8th version of the AJCC TNM classification.&#xD;
&#xD;
          -  Assessed at a multidisciplinary conference to be suitable for curatively intended&#xD;
             oncological and surgical treatment.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Performance status ECOG 0-2.&#xD;
&#xD;
          -  Patient has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy in the thorax (except for tangential field radiotherapy for&#xD;
             breast cancer).&#xD;
&#xD;
          -  Inability to understand written and spoken instructions and to comply with protocol&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriella A von Döbeln, MD, PhD</last_name>
    <phone>+46 8 517 700 00</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Alexandersson von Dobeln, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 16, 2021</last_update_submitted>
  <last_update_submitted_qc>May 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Gabriella Alexandersson von Döbeln</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

